|
|
|
PVCT Provectus Biopharmaceuticals
|
 |
||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: It is clear that big pharma sees oncolytic viruses as an increasingly important part of the anticancer combination armoury.Not specifically NET and/or MUM, but here are 2 trials T-vec is doing in liver cancer http://clinicaltrials.gov/ct2/show/NCT02509507 This one started as monotherapy with 100 patients now its combo trial with pembrolizumab 244 patients http://clinicaltrials.gov/ct2/show/NCT03256344 This one is in combination also huge market potential as majority of Colorectal and Breast have liver metastases (>50%).
|
|||||||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 2646 | Re: It is clear that big pharma sees oncolytic viruses as an increasingly important part of the anticancer combination armoury. | pvctmagic | 0 | 9/20/2018 12:28:32 PM |
